• Catalan
  • Dutch
  • English
  • Spanish
Health Outcomes Observatory
  • Home
  • Project
    • About H2O
    • Vision & Objectives
    • Impact
    • Work Packages
    • Governance
  • Participants
    • Partners
    • Associated Collaborators
    • Advisory Boards
  • Observatories
    • What are the Observatories?
    • How do they work?
  • Patients
    • H2O, with and for patients
    • FAQs
    • PROs Leaflet
  • News
    • News
    • Press Releases & Announcements
    • Events
    • Blogs
  • Resources
    • Publications
    • Deliverables
    • Factsheets
  • Contact
  • Search
  • Menu Menu
  • Home
  • Project
    • About H2O
    • Vision & Objectives
    • Impact
    • Work Packages
    • Governance
  • Participants
    • Partners
    • Associated Collaborators
    • Advisory Boards
  • Observatories
    • What are the Observatories?
    • How do they work?
  • Patients
    • H2O, with and for patients
    • FAQs
    • PROs Leaflet
  • News
    • News
    • Press Releases & Announcements
    • Events
    • Blogs
  • Resources
    • Publications
    • Deliverables
    • Factsheets
  • Contact

Understanding the importance and value of Patient-reported outcomes

27th May 2021/in blog /by Renn

by Francesco Patalano

I am a physician, a Pharma R&D executive and, from time to time, a patient – we all are. As a patient, I sometimes find it difficult to describe to the doctor treating me the subjective impact of a disease or the effect of a medication on my overall wellbeing.

The FDA defines Patient-Reported Outcomes (PRO) as reports of a patient’s health condition and health-related quality of life that comes directly from the patient, without anyone else’s interpretation. Because some effects of the disease are known only to the patients, collecting the information directly from the patient who experiences them is absolutely critical to measure the impact of a disease or the efficacy of a drug.

Pain, itch, lack of energy and tiredness are common situations for patients suffering from a number of conditions. However, they are only known to the patients who experience them and cannot be measured by a laboratory test.

Only a patient can describe an episode of migraine affecting the ability to work or the relationship with other family members. These events may be the only manifestation of a disease and will not be measured by any laboratory analysis!

PROs are tools to standardize collection of this information. PROs include information about health-related quality of life, symptoms, functional status, satisfaction with treatments, adherence to treatment, and perceived value of treatment. They are therefore powerful tools to empower patients to engage in their own health care over time. PROs are also important to inform and advance health care decisions based on clear evidences, which will ultimately affect them and many other patients as well.

Using PRO instruments, patients can convey clearly to their physicians their subjective feelings and concerns, including positive or negative effects on quality of life and what they consider as important. Vice-versa, information on what to expect in the course of a disease or following a treatment can be communicated to the patients using the PRO information as starting point and reference. Thus, PROs are very effective in promoting dialogue between physicians and their patients using a language that is understood by both.

Both the patient and medical community should expand the use of PROs to improve overall communication and clinical decision-making. It is, however, important to align on the purpose of data collection, how this data is stored, and the reporting and analyses of the data to avoid any ethical concerns, optimize resources and not overburden patients and implementers.

More efforts are needed to develop PRO instruments in areas of unmet needs. It is, however, undeniably clear that PROs are invaluable to all the stakeholders right from effective outcomes measurement, addressing patient needs, assessing drug efficacy, and discussions concerning the access to medicines. They are the key driver in the patient-centric era of outcomes driving medical decisions and drug development, enabling patients to have a central role in the process.

In considering PRO a critical part of the Health Data – free to flow, but ultimately owned by the patients – the IMI H2O Project will improve communication between individual patients and their physicians and will facilitate value-based healthcare decisions. I am delighted and proud to be part of this exciting journey.

Share this entry
  • Share on Twitter
  • Share on LinkedIn
  • Share by Mail
https://health-outcomes-observatory.eu/wp-content/uploads/2021/05/FPatalano_wide.jpg 1337 2009 Renn https://health-outcomes-observatory.eu/wp-content/uploads/2021/01/H2O-logo-hor-300x98.png Renn2021-05-27 14:44:232021-05-27 14:54:09Understanding the importance and value of Patient-reported outcomes

NEWSLETTER

Sign up to stay informed

Recent Posts

  • Creation of the independent legal entity of the H20 (Health Outcomes Observatory) project in Spain.
  • H2O response to the new European Health Data Space (EHDS)
  • Unleashing the Power of PROS – an H2O Hosted Conversation
  • Please join us for our Open House Sessions in May 2022

ACKNOWLEDGEMENT

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 945345-2. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and Trial Nation and JDRF.

About IMI

The Innovative Medicines Initiative is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). It is working to improve health by speeding up the development of the next generation of medicines, particularly in areas where there is an unmet medical or social need. It works by facilitating collaboration between the key players involved in health research, including universities, research centres, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. IMI is the world’s biggest public-private partnership (PPP) in the life sciences. http://www.imi.europa.eu/

Legal notice
Privacy Policy
Cookies Policy

       




Request for proposal for H2O’s international observatory – extension until... Quote: “We are delighted that NEJM Catalyst has published a concept paper outlining our process for H2O, the largest-ever ecosystem for incorporating patient-reported and other health outcomes into healthcare decision-making across multiple European countries. We believe this project will be a vital step towards embedding value-based care across Europe.” Read H2O’s new paper
Scroll to top
Non exempt cookies, proprietary cookies and third-party cookies are used to identify the browsing preferences and habits of users and to offer a better experience. Please consult our cookie policy here.
Cookie SettingsAccept all Reject All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT